Sign In
Buy AGIO
$27.68
+1.17 (+4.41%)
At Close: Jun 03, 2026
Wall Street Analysts See a 26.01% Upside in Agios Pharmaceuticals (AGIO): Can the Stock Really Move This High?
10:56am, Wednesday, 08'th May 2024
The consensus price target hints at a 26% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
01:26pm, Friday, 03'rd May 2024
Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024
07:00am, Friday, 03'rd May 2024
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates
09:31am, Thursday, 02'nd May 2024
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.45 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to loss of $1.47 per share a year ago.
Agios Reports Business Highlights and First Quarter 2024 Financial Results
07:00am, Thursday, 02'nd May 2024
– Topline Data Readout from the Phase 3 ENERGIZE-T Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia now expected in Q2 2024 –
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
11:06am, Thursday, 25'th Apr 2024
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
07:00am, Thursday, 18'th Apr 2024
CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announc
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
04:30pm, Tuesday, 16'th Apr 2024
Some of the hottest opportunities can be found in biotech stocks to buy now. With innovation, mergers and acquisitions, major companies looking to replenish their pipelines ahead of patent expirations
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024
07:00am, Tuesday, 05'th Mar 2024
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announc
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
07:00am, Thursday, 22'nd Feb 2024
CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced tha
Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates
10:41am, Friday, 16'th Feb 2024
Agios' (AGIO) earnings and revenues miss estimates in the fourth quarter of 2023. Revenues from its sole marketed drug, Pyrukynd, rise year over year.
Agios Pharmaceuticals (AGIO) Q4 2023 Earnings Call Transcript
02:08pm, Thursday, 15'th Feb 2024
Agios Pharmaceuticals (AGIO) Q4 2023 Earnings Call Transcript
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue Estimates
09:26am, Thursday, 15'th Feb 2024
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.72 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to earnings of $0.67 per share a year ago.
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
07:00am, Thursday, 15'th Feb 2024
– Announced Positive Results from the Phase 3 ENERGIZE Study of Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia – – Presented Positive Results from Phase 2 Portion
7 Biotech Stocks Fighting America's Deadliest Diseases
04:10pm, Thursday, 08'th Feb 2024
Unlike many other market segments, biotech stocks stand out for their direct relevance. For example, investors who typically wager on aerospace and defense plays usually aren't fighter pilots.
